Analytical Data
-
Gene name
RFPL3
- Application
-
Alternative Names
RFPL3; Ret finger protein-like 3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75679
-
Expression Region
1-317 aa
-
AA Sequence
MKRLSLVTTN RLSPQGNFLP LCTFPLAVDM AALFQEASSC PVCSDYLEKP MSLECGCTVC LKCINSLQKE PHGEDLLCCC CSMVSQRNKI RPNRQLERLV SHIKELEPKL KKILQMNPRM RKFQVDMTLD ADTANNFLLI SDDLRSVRSG LITQNRQDLA ERFDVSVCIL GSPRFTCGRH YWEVDVGTST EWDLGVCRES VHCKGKIQLT TELGFWTVSL RDGSRLSAST VPLTFLLVDR KLQRVGIFLD MGMQNVSFFD AESGSHVYTF RSVSAEEPLR PFLAPSIPPN GDQGVLSICP LMNSGTTDAP VRPGEAK
-
Molecular Weight
35.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
RFPL3, or RNA-binding Fox-1 homolog 3, is a member of the RFPL (RNA-binding Fox-1/2/p1-like) protein family, characterized by an RNA recognition motif (RRM) and implicated in post-transcriptional regulation of gene expression. Recent studies have highlighted RFPL3's pivotal role in various biological processes, including cellular differentiation and proliferation, suggesting its potential involvement in cancer biology and other diseases. The protein's ability to bind specifically to certain RNA sequences positions it as a key player in the regulation of alternative splicing and mRNA stability, making it an attractive target for therapeutic interventions. Moreover, the aberrant expression of RFPL3 has been linked to several malignancies, prompting investigations into its function and mechanisms of action. Understanding RFPL3's structure and function through the development of recombinant protein can provide insights into its role in cellular processes and its potential as a biomarker or target in cancer therapies. This encompasses the need for high-quality recombinant protein for in vitro and in vivo studies, which could unveil novel therapeutic strategies focused on modulating RFPL3's activity within pathological contexts. Hence, ongoing research into RFPL3 and its recombinant forms aims to elucidate its molecular mechanisms and evaluate its potential as a therapeutic target in oncological applications.
